The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin - Related Studies

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

This study has been completed.

Study NCT00031343. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections
		Hepatitis C

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Hepatitis
		Infection

3	More general conditions related to this trial
		Digestive System Diseases
		Flaviviridae Infections
		Hepatitis, Viral, Human
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Liver Diseases
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Additional drug interventions recognized in this trial
		Peginterferon alfa-2b

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antiviral Agents
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)